Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Forgot Sakai
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by ANALIAS00on Nov 12, 2022 9:13pm
72 Views
Post# 35094317

RE:RE:RE:RE:RE:RE:RE:Forgot Sakai

RE:RE:RE:RE:RE:RE:RE:Forgot Sakai It is sad to say they will prove their poor communication strategy if they come out with good news. Because the way they act can only be justify by result not being what they were expecting.
PWIB123 wrote: I guess you could look at that several ways, but obviously invstors wanted more and weren't given those details.  The success of the lawsuit's defense seems to have emboldened THTX to stick to their history of providing less communication.  I would've agreed with the courts on this one.  I think they made the right call, but that doesn't mean THTX is doing the right thing in how they communicate with investors.  

Lee430 wrote: Perhaps this is the reason for their ultra conservative PR stance.

https://www.theglobeandmail.com/report-on-business/industry-news/the-law-page/top-court-tosses-suit-against-theratechnologies/article24004231/

Joemare wrote: I think it's fine to voice your opinion. Not sure how busy she is. Very quiet on linked-in and twitter.....

 






<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities